Position
D. E. Shaw & Co., Inc. in Maxcyte, Inc.
Back to the book · All holders of MXCT
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$169.9K$1.55 → $0.70
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 664K | $1.03M | — | — | — | 0.0% |
| Q1 2026 | 200.5K | $140.9K | $0.70 | −$169.9K | −$718.3K | 0.0% |